|drug1864||Lopinavir-Ritonavir Drug Combination Wiki||1.00|
|drug3195||Standard Care Wiki||0.50|
There is one clinical trial.
CovidSurg will capture real-world international data, to determine 30-day mortality in patients with COVID-19 infection who undergo surgery. This shared international experience will inform the management of this complex group of patients who undergo surgery throughout the COVID-19 pandemic, ultimately improving their clinical care.
Description: Death up to 30-days post surgeryMeasure: 30-day mortality Time: 30 days
Description: Death up to 7-days post surgeryMeasure: 7-day mortality Time: 7 days post surgery
Description: Reoperation up to 30-days post surgeryMeasure: 30-day reoperation Time: Up to 30-days post surgery
Description: Admission to ICU post surgeryMeasure: Postoperative ICU admission Time: Up to 30 days post surgery
Description: Respiratory failure post surgeryMeasure: Postoperative respiratory failure Time: Up to 30 days post surgery
Description: Acute respiratory distress syndrome post surgeryMeasure: Postoperative acute respiratory distress syndrome (ARDS) Time: Up to 30 days post surgery
Description: Sepsis post surgeryMeasure: Postoperative sepsis Time: Up to 30 days post surgery
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports